Zahra Foruzandeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zahra Foruzandeh has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Reza Alivand
Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
7 shared publications Bahareh Kazemi
Division of Hematology and Blood Banking, Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publicationsFatemeh Najafi
Division of Hematology and Blood Banking, Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publicationsShohre Karimi Kelaye
Division of Hematology and Blood Banking, Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publicationsDavood Ghavi
Department of Genetics, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publicationsFarhad Seif
Department of Immunology and Allergy, Academic Center for Education, Culture, and Research, Tehran, Iran
3 shared publications
Latest Publications
- 17 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Combined effects of 5-azacytidine and oleuropein on miR-149-3p, miR-375, miR-574-5p expression and apoptosis in acute myeloid leukemia (AML) cell lines HL-60 and THP-1
Background Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloid cells and poor clinical outcomes. Despite conventional treatments such as chemotherapy and hematopoietic stem cell transplantation, relapse and resistance remain major challenges. Epigenetic alterations—particularly dysregulated DNA methylation and microRNA (miRNA) expression- are crucial in AML pathogenesis. Objective This study aimed to investigate the synergistic effects of azacitidine, a DNA methyltransferase inhibitor, and oleuropein, a natural polyphenol with anticancer properties, on AML cell lines (THP-1 and HL-60). Methods AML cells were treated with azacitidine, oleuropein, or their combination. Cell proliferation was evaluated using MTT assays, apoptosis was assessed via flow cytometry (Annexin V-FITC/PI staining), and miRNA expression levels were quantified using real-time PCR. Results Both azacitidine and oleuropein reduced cell viability and induced apoptosis in a dose- and time-dependent manner. The combination treatment significantly enhanced apoptosis, resulting in a 2.5-fold increase in Annexin V-positive HL-60 cells at 72 h. Additionally, the treatment modulated miRNA expression, upregulating miR-149-3p and miR-375, while downregulating miR-574-5p. Conclusion The synergistic effects of oleuropein and azacitidine suggest a promising therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are warranted to validate these findings and optimize treatment protocols.
- 17 October 2025
- Published by Springer Nature in Molecular Biology Reports
- Vol. 52 (1) , 1-9
Combined effects of 5-azacytidine and oleuropein on miR-149-3p, miR-375, miR-574-5p expression and apoptosis in acute myeloid leukemia (AML) cell lines HL-60 and THP-1
Background Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid proliferation of immature myeloid cells and poor clinical outcomes. Despite conventional treatments such as chemotherapy and hematopoietic stem cell transplantation, relapse and resistance remain major challenges. Epigenetic alterations—particularly dysregulated DNA methylation and microRNA (miRNA) expression- are crucial in AML pathogenesis. Objective This study aimed to investigate the synergistic effects of azacitidine, a DNA methyltransferase inhibitor, and oleuropein, a natural polyphenol with anticancer properties, on AML cell lines (THP-1 and HL-60). Methods AML cells were treated with azacitidine, oleuropein, or their combination. Cell proliferation was evaluated using MTT assays, apoptosis was assessed via flow cytometry (Annexin V-FITC/PI staining), and miRNA expression levels were quantified using real-time PCR. Results Both azacitidine and oleuropein reduced cell viability and induced apoptosis in a dose- and time-dependent manner. The combination treatment significantly enhanced apoptosis, resulting in a 2.5-fold increase in Annexin V-positive HL-60 cells at 72 h. Additionally, the treatment modulated miRNA expression, upregulating miR-149-3p and miR-375, while downregulating miR-574-5p. Conclusion The synergistic effects of oleuropein and azacitidine suggest a promising therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are warranted to validate these findings and optimize treatment protocols.
- Open Access
- 17 July 2025
- Published by Springer Nature in Research Square
Combined Effects of 5-Azacytidine and Oleuropein on miR-149-3p, miR-375, miR-574-5p Expression and Apoptosis in HL-60 and THP-1 Cell Lines
Background Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid expansion of immature myeloid cells and poor clinical outcomes. Despite conventional treatments, including chemotherapy and hematopoietic stem cell transplantation, relapse and resistance remain significant challenges. Epigenetic alterations, particularly dysregulated DNA methylation and microRNA (miRNA) expression, play a crucial role in AML pathogenesis. Objective This study aimed to evaluate the synergistic effects of azacitidine, a DNA methyltransferase inhibitor, and oleuropein, a natural polyphenol with anticancer properties, on AML cell lines (THP-1 and HL-60). Methods AML cells were treated with azacitidine, oleuropein, and their combination. Cell proliferation was assessed using MTT assays, apoptosis was analyzed via flow cytometry (Annexin V-FITC/PI staining), and miRNA expression levels were quantified using real-time PCR. Results Both azacitidine and oleuropein reduced cell viability and induced apoptosis in a dose- and time-dependent manner. Notably, the combination treatment significantly enhanced apoptosis, with a 2.5-fold increase in Annexin V-positive HL-60 cells at 72 hours. Furthermore, the treatment modulated miRNA expression, upregulating miR-149-3p and miR-375 while downregulating miR-574-5p. Conclusion The synergistic effects of oleuropein and azacitidine suggest a potential therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are necessary to validate these findings and optimize treatment protocols.
- 17 July 2025
- Published by Springer Nature in Research Square
Open AccessCombined Effects of 5-Azacytidine and Oleuropein on miR-149-3p, miR-375, miR-574-5p Expression and Apoptosis in HL-60 and THP-1 Cell Lines
Background Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by the rapid expansion of immature myeloid cells and poor clinical outcomes. Despite conventional treatments, including chemotherapy and hematopoietic stem cell transplantation, relapse and resistance remain significant challenges. Epigenetic alterations, particularly dysregulated DNA methylation and microRNA (miRNA) expression, play a crucial role in AML pathogenesis. Objective This study aimed to evaluate the synergistic effects of azacitidine, a DNA methyltransferase inhibitor, and oleuropein, a natural polyphenol with anticancer properties, on AML cell lines (THP-1 and HL-60). Methods AML cells were treated with azacitidine, oleuropein, and their combination. Cell proliferation was assessed using MTT assays, apoptosis was analyzed via flow cytometry (Annexin V-FITC/PI staining), and miRNA expression levels were quantified using real-time PCR. Results Both azacitidine and oleuropein reduced cell viability and induced apoptosis in a dose- and time-dependent manner. Notably, the combination treatment significantly enhanced apoptosis, with a 2.5-fold increase in Annexin V-positive HL-60 cells at 72 hours. Furthermore, the treatment modulated miRNA expression, upregulating miR-149-3p and miR-375 while downregulating miR-574-5p. Conclusion The synergistic effects of oleuropein and azacitidine suggest a potential therapeutic strategy for AML by targeting epigenetic mechanisms and miRNA pathways. Further in vivo studies and clinical trials are necessary to validate these findings and optimize treatment protocols.
- Open Access
- 27 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (11) , 16-30
Network-based meta-analysis and confirmation of genes ATP1A2, FXYD1, and ADCY3 associated with cAMP signaling in breast tumors compared to corresponding normal marginal tissues
Breast cancer (BC) is a global health concern with a growing prevalence. Since BC is a heterogeneous cancer, transcriptome analyzes were carried out on breast tumor tissues relative to their corresponding normal tissues in order to identify gene expression signatures and perform meta-analysis. Five expression profiling by array data sets from breast tumor tissues and non-tumor neighboring tissues were retrieved following a search in the GEO database (GSE70947, GSE70905, GSE10780, GSE29044, and GSE42568). Meta-analysis of gene expression using the Network Analyst tool identified common differentially expressed genes and biological pathways in all data sets. Then, the DEGs were analyzed through PPI network construction, gene ontology, and pathway analysis. The detected hub genes underwent Kaplan-Meier (KM) plotter and UALCAN validation. Finally, Real-time PCR analysis was used on BC patients' samples to determine mRNA levels of cAMP signaling pathway members ATP1A2, FXYD1, and ADCY3. Breast tumor tissues showed 710 differentially expressed genes (DEGs), with 392 overexpressed and 318 underexpressed, compared to normal marginal tissues. On the EnrichR library, GO, and KEGG pathway analyses were performed on the DEGs list. Progesterone-mediated oocyte maturation and the NF-kappa B signaling system were upregulated DEGs' top deregulated signaling pathways. In contrast, pathways related to cancer and the cAMP signaling pathway were the most enriched terms for down-regulated genes. Next, Real-time PCR quantification of cAMP signaling cascade members ATP1A2, FXYD1, and ADCY3 was performed on 50 BC tumoral and non-tumoral tissues for validation. Results of meta-analyzed array data sets revealed DEGs representing BC gene signatures, and cAMP signaling pathway members as effective factors in BC. The results of our real-time PCR expression level determination for ATP1A2, FXYD1, and ADCY3 in breast tumor tissues relative to the normal margins contradicted our bioinformatics investigations, which found increased levels for these genes. Of these, only ATP1A2's expression levels were statistically significant. This study focused on identifying gene expression signatures that provide an invaluable source of evidence for BC-related underlying mechanisms to provide new therapeutic targets and biomarkers.
- 27 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (11) , 16-30
Open AccessNetwork-based meta-analysis and confirmation of genes ATP1A2, FXYD1, and ADCY3 associated with cAMP signaling in breast tumors compared to corresponding normal marginal tissues
Breast cancer (BC) is a global health concern with a growing prevalence. Since BC is a heterogeneous cancer, transcriptome analyzes were carried out on breast tumor tissues relative to their corresponding normal tissues in order to identify gene expression signatures and perform meta-analysis. Five expression profiling by array data sets from breast tumor tissues and non-tumor neighboring tissues were retrieved following a search in the GEO database (GSE70947, GSE70905, GSE10780, GSE29044, and GSE42568). Meta-analysis of gene expression using the Network Analyst tool identified common differentially expressed genes and biological pathways in all data sets. Then, the DEGs were analyzed through PPI network construction, gene ontology, and pathway analysis. The detected hub genes underwent Kaplan-Meier (KM) plotter and UALCAN validation. Finally, Real-time PCR analysis was used on BC patients' samples to determine mRNA levels of cAMP signaling pathway members ATP1A2, FXYD1, and ADCY3. Breast tumor tissues showed 710 differentially expressed genes (DEGs), with 392 overexpressed and 318 underexpressed, compared to normal marginal tissues. On the EnrichR library, GO, and KEGG pathway analyses were performed on the DEGs list. Progesterone-mediated oocyte maturation and the NF-kappa B signaling system were upregulated DEGs' top deregulated signaling pathways. In contrast, pathways related to cancer and the cAMP signaling pathway were the most enriched terms for down-regulated genes. Next, Real-time PCR quantification of cAMP signaling cascade members ATP1A2, FXYD1, and ADCY3 was performed on 50 BC tumoral and non-tumoral tissues for validation. Results of meta-analyzed array data sets revealed DEGs representing BC gene signatures, and cAMP signaling pathway members as effective factors in BC. The results of our real-time PCR expression level determination for ATP1A2, FXYD1, and ADCY3 in breast tumor tissues relative to the normal margins contradicted our bioinformatics investigations, which found increased levels for these genes. Of these, only ATP1A2's expression levels were statistically significant. This study focused on identifying gene expression signatures that provide an invaluable source of evidence for BC-related underlying mechanisms to provide new therapeutic targets and biomarkers.
- Open Access
- 28 December 2023
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 44
Identification of dysregulated miRNAs and their roles in breast cancer; An in silico meta‐analysis study
- 28 December 2023
- Published by Elsevier in Informatics in Medicine Unlocked
- Vol. 44
Open AccessIdentification of dysregulated miRNAs and their roles in breast cancer; An in silico meta‐analysis study
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (9) , 921-933
The Importance of mir-491-5p in Various Cancers
MicroRNAs are non-coding ribonucleic acids that are evolutionarily protected. MiRNAs control the expression of genes after transcription by mRNA decomposition or the inhibition of their translation. These molecular structures control physiological and pathological processes; therefore, many of them can play vital roles as oncogenes or tumor inhibitors. Besides, the occurrence of various mutations in miRNAs can lead to cancer. In this review article, we want to peruse the role of miR-491-5p in various cancers. In recent years, many experiments and studies have been performed on the involvement of miR-491-5p in cancer, invasion, and cell metastasis. Metastasis is an event that makes cancer more advanced and harder to treat. When cancer is invasive, the cancer cells invade nearby tissues or other organs and develop cancer. Tumor studies have shown that miR-491-5p can inhibit cell growth, invasion, and metastasis. Thus, expression enhancement of miR-491-5p disrupts cell migration and improves cancer.
- 1 November 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (9) , 921-933
The Importance of mir-491-5p in Various Cancers
MicroRNAs are non-coding ribonucleic acids that are evolutionarily protected. MiRNAs control the expression of genes after transcription by mRNA decomposition or the inhibition of their translation. These molecular structures control physiological and pathological processes; therefore, many of them can play vital roles as oncogenes or tumor inhibitors. Besides, the occurrence of various mutations in miRNAs can lead to cancer. In this review article, we want to peruse the role of miR-491-5p in various cancers. In recent years, many experiments and studies have been performed on the involvement of miR-491-5p in cancer, invasion, and cell metastasis. Metastasis is an event that makes cancer more advanced and harder to treat. When cancer is invasive, the cancer cells invade nearby tissues or other organs and develop cancer. Tumor studies have shown that miR-491-5p can inhibit cell growth, invasion, and metastasis. Thus, expression enhancement of miR-491-5p disrupts cell migration and improves cancer.
- 1 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 249, 154576
The role of mir-151a-5p in tumorigenesis; A systematic review
- 1 June 2023
- Published by Elsevier in Pathology - Research and Practice
- Vol. 249, 154576
The role of mir-151a-5p in tumorigenesis; A systematic review
- Open Access
- 8 May 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-12
Identification and validation of miR-583 and mir-877-5p as biomarkers in patients with breast cancer: an integrated experimental and bioinformatics research
Objectives: Breast cancer (BC) is one of the most common cancers with a high mortality rate in women worldwide. The advantages of early cancer diagnosis are apparent, and it is a critical factor in increasing the patient’s life and survival. According to mounting evidence, microRNAs (miRNAs) may be crucial regulators of critical biological processes. miRNA dysregulation has been linked to the beginning and progression of various human malignancies, including BC, and can operate as tumor suppressors or oncomiRs. This study aimed to identify novel miRNA biomarkers in BC tissues and non-tumor adjacent tissues of patients with BC. Microarray datasets GSE15852 and GSE42568 for differentially expressed genes (DEGs) and GSE45666, GSE57897, and GSE40525 for differentially expressed miRNAs (DEMs) retrieved from the Gene Expression Omnibus (GEO) database were analyzed using “R” software. A protein-protein interaction (PPI) network was created to identify the hub genes. MirNet, miRTarBase, and MirPathDB databases were used to predict DEMs targeted genes. Functional enrichment analysis was used to demonstrate the topmost classifications of molecular pathways. The prognostic capability of selected DEMs was evaluated through a Kaplan-Meier plot. Moreover, the specificity and sensitivity of detected miRNAs to discriminate BC from adjacent controls were assessed by area under the curve (AUC) using the ROC curve analysis. In the last phase of this study, gene expression on 100 BC tissues and 100 healthy adjacent tissues were analyzed and calculated by using the Real-Time PCR method. Results: This study declared that miR-583 and miR-877-5p were downregulated in tumor samples in comparison to adjacent non-tumor samples (|logFC|< 0 and P ≤ 0.05). Accordingly, ROC curve analysis demonstrated the biomarker potential of miR-877-5p (AUC = 0.63) and miR-583 (AUC = 0.69). Our results showed that has-miR-583 and has-miR-877-5p could be potential biomarkers in BC.
- 8 May 2023
- Published by Springer Nature in BMC Research Notes
- Vol. 16 (1) , 1-12
Open AccessIdentification and validation of miR-583 and mir-877-5p as biomarkers in patients with breast cancer: an integrated experimental and bioinformatics research
Objectives: Breast cancer (BC) is one of the most common cancers with a high mortality rate in women worldwide. The advantages of early cancer diagnosis are apparent, and it is a critical factor in increasing the patient’s life and survival. According to mounting evidence, microRNAs (miRNAs) may be crucial regulators of critical biological processes. miRNA dysregulation has been linked to the beginning and progression of various human malignancies, including BC, and can operate as tumor suppressors or oncomiRs. This study aimed to identify novel miRNA biomarkers in BC tissues and non-tumor adjacent tissues of patients with BC. Microarray datasets GSE15852 and GSE42568 for differentially expressed genes (DEGs) and GSE45666, GSE57897, and GSE40525 for differentially expressed miRNAs (DEMs) retrieved from the Gene Expression Omnibus (GEO) database were analyzed using “R” software. A protein-protein interaction (PPI) network was created to identify the hub genes. MirNet, miRTarBase, and MirPathDB databases were used to predict DEMs targeted genes. Functional enrichment analysis was used to demonstrate the topmost classifications of molecular pathways. The prognostic capability of selected DEMs was evaluated through a Kaplan-Meier plot. Moreover, the specificity and sensitivity of detected miRNAs to discriminate BC from adjacent controls were assessed by area under the curve (AUC) using the ROC curve analysis. In the last phase of this study, gene expression on 100 BC tissues and 100 healthy adjacent tissues were analyzed and calculated by using the Real-Time PCR method. Results: This study declared that miR-583 and miR-877-5p were downregulated in tumor samples in comparison to adjacent non-tumor samples (|logFC|< 0 and P ≤ 0.05). Accordingly, ROC curve analysis demonstrated the biomarker potential of miR-877-5p (AUC = 0.63) and miR-583 (AUC = 0.69). Our results showed that has-miR-583 and has-miR-877-5p could be potential biomarkers in BC.
- Open Access
- 6 March 2023
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 24 (1) , 1-14
Mutual interaction of lncRNAs and epigenetics: focusing on cancer
Long noncoding RNAs are characterized as noncoding transcripts longer than 200 nucleotides in response to a variety of functions within the cells. They are involved in almost all cellular mechanisms so as epigenetics. Given that epigenetics is an important phenomenon, which participates in the biology of complex diseases, many valuable studies have been performed to demonstrate the control status of lncRNAs and epigenetics. DNA methylation and histone modifications as epigenetic mechanisms can regulate the expression of lncRNAs by affecting their coding genes. Reciprocally, the three-dimensional structure of lncRNAs could mechanistically control the activity of epigenetic-related enzymes. Dysregulation in the mutual interaction between epigenetics and lncRNAs is one of the hallmarks of cancer. These mechanisms are either directly or indirectly involved in various cancer properties such as proliferation, apoptosis, invasion, and metastasis. For instance, lncRNA HOTAIR plays a role in regulating the expression of many genes by interacting with epigenetic factors such as DNA methyltransferases and EZH2, and thus plays a role in the initiation and progression of various cancers. Conversely, the expression of this lncRNA is also controlled by epigenetic factors. Therefore, focusing on this reciprocated interaction can apply to cancer management and the identification of prognostic, diagnostic, and druggable targets. In the current review, we discuss the reciprocal relationship between lncRNAs and epigenetic mechanisms to promote or prevent cancer progression and find new potent biomarkers and targets for cancer diagnosis and therapy.
- 6 March 2023
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 24 (1) , 1-14
Open AccessMutual interaction of lncRNAs and epigenetics: focusing on cancer
Long noncoding RNAs are characterized as noncoding transcripts longer than 200 nucleotides in response to a variety of functions within the cells. They are involved in almost all cellular mechanisms so as epigenetics. Given that epigenetics is an important phenomenon, which participates in the biology of complex diseases, many valuable studies have been performed to demonstrate the control status of lncRNAs and epigenetics. DNA methylation and histone modifications as epigenetic mechanisms can regulate the expression of lncRNAs by affecting their coding genes. Reciprocally, the three-dimensional structure of lncRNAs could mechanistically control the activity of epigenetic-related enzymes. Dysregulation in the mutual interaction between epigenetics and lncRNAs is one of the hallmarks of cancer. These mechanisms are either directly or indirectly involved in various cancer properties such as proliferation, apoptosis, invasion, and metastasis. For instance, lncRNA HOTAIR plays a role in regulating the expression of many genes by interacting with epigenetic factors such as DNA methyltransferases and EZH2, and thus plays a role in the initiation and progression of various cancers. Conversely, the expression of this lncRNA is also controlled by epigenetic factors. Therefore, focusing on this reciprocated interaction can apply to cancer management and the identification of prognostic, diagnostic, and druggable targets. In the current review, we discuss the reciprocal relationship between lncRNAs and epigenetic mechanisms to promote or prevent cancer progression and find new potent biomarkers and targets for cancer diagnosis and therapy.
- 16 September 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 239, 154130
The role of miRNA-424 and miR-631 in various cancers: Focusing on drug resistance and sensitivity
- 16 September 2022
- Published by Elsevier in Pathology - Research and Practice
- Vol. 239, 154130
The role of miRNA-424 and miR-631 in various cancers: Focusing on drug resistance and sensitivity
- 10 May 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (10) , 9825-9840
Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review
More effective prognostic and diagnostic tools are urgently required for early detecting and treating triple-negative breast cancer, which is the most acute type of breast cancer because of its lower survival rate, aggressiveness, and non-response to various common treatments. So, it remains the most harmful malignancy for women worldwide. Recently, circular RNAs, as a group of non-coding RNAs, with covalently closed loop and high stability have been discovered, which can modulate gene expression through competing with endogenous microRNA sponges. This finding provided further insight into novel approaches for controlling genes affected in many disorders and malignancies. This review concentrates on the dysregulated expression of circRNAs like their diagnostic and prognostic values in TNBC. This review aims to focus on the abnormal expression of circRNAs and their diagnostic and prognostic values in TNBC. We used PubMed, Embase, and Web of Science databases and ClinicalTrials.gov to systematically search for all relevant clinical studies. This review is based on articles published in databases up to April 2022 with the following keywords: “Circular RNA”, “CircRNA”, “Triple-Negative Breast Cancer” and “TNBC”. We conducted a review of published CircRNA profiled-research articles to identify candidate CircRNA biomarkers for TNBC. The review is registered on JBI at https://jbi.global/systematic-review-register. Accumulating evidence has shown that several circRNAs are downregulated and some are upregulated in TNBC. The results of these studies confirm that circRNAs might be potential biomarkers with the diagnostic, prognostic, and therapeutic target value for TNBC. We also consider the connection between circRNAs and TNBC cell proliferation, apoptosis, metastasis, and chemotherapy resistance and sensitivity.
- 10 May 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 49 (10) , 9825-9840
Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review
More effective prognostic and diagnostic tools are urgently required for early detecting and treating triple-negative breast cancer, which is the most acute type of breast cancer because of its lower survival rate, aggressiveness, and non-response to various common treatments. So, it remains the most harmful malignancy for women worldwide. Recently, circular RNAs, as a group of non-coding RNAs, with covalently closed loop and high stability have been discovered, which can modulate gene expression through competing with endogenous microRNA sponges. This finding provided further insight into novel approaches for controlling genes affected in many disorders and malignancies. This review concentrates on the dysregulated expression of circRNAs like their diagnostic and prognostic values in TNBC. This review aims to focus on the abnormal expression of circRNAs and their diagnostic and prognostic values in TNBC. We used PubMed, Embase, and Web of Science databases and ClinicalTrials.gov to systematically search for all relevant clinical studies. This review is based on articles published in databases up to April 2022 with the following keywords: “Circular RNA”, “CircRNA”, “Triple-Negative Breast Cancer” and “TNBC”. We conducted a review of published CircRNA profiled-research articles to identify candidate CircRNA biomarkers for TNBC. The review is registered on JBI at https://jbi.global/systematic-review-register. Accumulating evidence has shown that several circRNAs are downregulated and some are upregulated in TNBC. The results of these studies confirm that circRNAs might be potential biomarkers with the diagnostic, prognostic, and therapeutic target value for TNBC. We also consider the connection between circRNAs and TNBC cell proliferation, apoptosis, metastasis, and chemotherapy resistance and sensitivity.